NRx Pharmaceuticals, Inc. (NRXP)

USD 1.55

(-5.79%)

Market Cap (In USD)

18.68 Million

Revenue (In USD)

-

Net Income (In USD)

-30.15 Million

Avg. Volume

79.61 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.1-7.33
PE
-
EPS
-
Beta Value
1.271
ISIN
US6294441000
CUSIP
089482103
CIK
1719406
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Stephen H. Willard Esq.
Employee Count
-
Website
https://www.nrxpharma.com
Ipo Date
2017-12-04
Details
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.